Published in Drug Week, June 9th, 2006
AN2690, the first in a new class of antifungal agents, is being developed for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 7% to 10% of the U.S. population. Two additional posters detailing AN2690's discovery and preclinical development were presented.
"These presentations illustrate the breadth of Anacor's boron chemistry and demonstrate that AN2690 is a potent antifungal drug, which acts directly on fungal infections in a new and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.